Steven Greenstein, MD
Ophthalmology · Teaneck, NJNPI 1255627501
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Glaukos Corporation at 51.3% of the total. 2025 is the largest year on record at $19,153, more than ten times the $92 reported in 2019. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $216.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$12K
- Ziemer USA$6K
- Oculus, Inc.$3K
- Sun Pharmaceutical Industries Inc.$309
- AbbVie$273
- Oyster Point Pharma, Inc.$199
- plus $861 from 18 others
Across 41 payments — averaging $749.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$16K
- Alcon Research LLC$15K
What the payments were for
- Consulting fees$9,00040%
- Speaking & faculty fees$9,17541%
- Travel & lodging$1,9639%
- Food & beverage$2,37211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 9 | $11,552 |
| Ziemer USA | 1 | $6,425 |
| Oculus, Inc. | 4 | $2,891 |
| Sun Pharmaceutical Industries Inc. | 19 | $309 |
| AbbVie(2 entities) | 9 | $273 |
| Oyster Point Pharma, Inc. | 11 | $199 |
| Kala Pharmaceuticals, Inc. | 11 | $151 |
| Tarsus Pharmaceuticals, Inc. | 7 | $122 |
| Biotissue Holdings Inc. | 4 | $81 |
| Harrow Eye, LLC | 5 | $78 |
| Bausch & Lomb Americas Inc. | 5 | $72 |
| Beaver-visitec International, Inc. | 1 | $61 |
| Dompe US, Inc. | 3 | $42 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 2 | $33 |
| Ocular Therapeutix, Inc. | 2 | $29 |
| Shire North American Group Inc | 2 | $26 |
| Rxsight Inc | 1 | $24 |
| Abbott | 1 | $24 |
| Sight Sciences, Inc. | 1 | $20 |
| Alcon | 1 | $17 |
| Alimera Sciences, Inc. | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epioxa$8,011
- FEMTOLDV$6,425
- Pentacam$2,750
- Travoprost Intraocular Implant - iDose$2,116
- KXL System$1,125
- NA$141
- Elahere$133
- Photrexa Viscous and Photrexa$131
How this compares
$22,510 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $15,570 |
| LumiganBimatoprost | 29 | $11,258 |
| Loteprednol Etabonate | 28 | $5,081 |
| Prednisolone Acetate | 105 | $4,939 |
| Bromfenac Sodium | 18 | $3,515 |
| Difluprednate | 21 | $2,769 |
| Brimonidine Tartrate | 16 | $2,413 |
| ValacyclovirValacyclovir Hcl | 45 | $2,269 |
| MoxifloxacinMoxifloxacin Hcl | 109 | $2,017 |
| Cevimeline Hcl | 13 | $1,636 |
| Gatifloxacin | 11 | $879 |
| Latanoprost | 16 | $294 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $200 |
| Ofloxacin | 12 | $151 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $273 | $26,82853 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $15 | $5,08128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Teaneck
- Peter HershTeaneck$68K
- Luis Gonzalez GonzalezTeaneck$58K
- Tamara LenisTeaneck$12K
- Ronald GlassmanTeaneck$9K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.